| Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2014 | 702 |
| Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer | Annals of Oncology | 2014 | 137 |
| Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up | European Journal of Surgical Oncology | 2014 | 137 |
| Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up | Radiotherapy and Oncology | 2014 | 116 |
| Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2014 | 112 |
| Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study | British Journal of Cancer | 2014 | 104 |
| Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up | European Journal of Surgical Oncology | 2014 | 98 |
| An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer | Oncologist | 2014 | 46 |
| TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial | Journal of the National Cancer Institute | 2014 | 44 |
| Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Radiotherapy and Oncology | 2014 | 25 |
| Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients | Antimicrobial Agents and Chemotherapy | 2014 | 21 |
| Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group | Clinical and Experimental Metastasis | 2014 | 15 |
| An investigation on the relationship between the occurrence of CMV DNAemia and the development of invasive aspergillosis in the allogeneic stem cell transplantation setting | Journal of Medical Virology | 2014 | 14 |
| Increased oxidative damage associated with unfavorable cytogenetic subgroups in chronic lymphocytic leukemia | BioMed Research International | 2014 | 9 |
| Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study | Clinical and Translational Oncology | 2014 | 7 |
| Single-nucleotide polymorphism array-based karyotyping of acute promyelocytic leukemia | PLoS ONE | 2014 | 6 |
| An evaluation of the role of NKG2C+ natural killer cells in protection from cytomegalovirus DNAemia early following allogeneic stem cell transplantation | Journal of Medical Virology | 2014 | 5 |
| The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona | Annals of Oncology | 2014 | 3 |
| Conventional induction and post-remission therapy in APL: have we arrived? | Best Practice and Research in Clinical Haematology | 2014 | 3 |
| Active cytomegalovirus infection is not a risk factor for Epstein-Barr virus DNAemia in the allogeneic stem cell transplantation setting | Clinical Transplantation | 2014 | |
| Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment. | Journal of Clinical Oncology | 2014 | |
| FCγRIIa and FCγRIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial. | Journal of Clinical Oncology | 2014 | |
